DADC
CTIC

D.A. Davidson & Co’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

D.A. Davidson & Co’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-200
Closed -$2K – 1874
2013
Q2 		$2K Buy
+200
New +$2.34K ﹤0.01% 1644

Other funds holding CTIC

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

D.A. Davidson & Co's CTIC Position: Q3 2013 in Review

D.A. Davidson & Co sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q3 2013, closing a stake of 200 shares — an estimated $2K sold.

D.A. Davidson & Co first reported a position in CTIC in Q2 2013 and held it in 1 quarter. The position peaked at $2K in Q2 2013. 67 funds tracked by Wall St. Rank hold CTIC as of Q3 2013.

  • D.A. Davidson & Co reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q3 2013 after selling out during the quarter.
  • D.A. Davidson & Co sold 200 CTI BioPharma Corp. (DE) Common Stock shares in Q3 2013, an estimated $2K.
  • D.A. Davidson & Co first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 1 quarter.
  • D.A. Davidson & Co's CTI BioPharma Corp. (DE) Common Stock position peaked at $2K in Q2 2013.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q3 2013.

Based on D.A. Davidson & Co's 13F filing for Q3 2013, filed 14 Nov 2013.